Ar-He knife combined with systemic chemotherapy for lung adenocarcinoma

    Patient: Sun, female, 52 years old, on November 4, 2009, chest CT examination showed: left lung lower lobe occupancy, considered lung cancer and lower lobe obstructive inflammation. on November 10, 2009, bronchoscopic brush examination + lung puncture pathological biopsy showed: lung adenocarcinoma. He came to our oncology department for the first time on Nov. 15, 2009. CT film at that time: Zhao Wenhua, Department of Minimally Invasive Oncology, Shandong Qianfo Mountain Hospital
 
    On November 18, 2009, he underwent CT-guided ar-helium knife treatment for left lung cancer in our department under local anesthesia. After the ar-helium knife puncture (white needle-like) and local ultra-low temperature freezing (minus 160 degrees), the tumor around the ar-helium knife showed obvious density reduction after freezing, and the tumor was completely “frozen to death”. As shown below.
 
    After the Ar-He knife surgery, the patient was treated with 3 cycles of systemic intravenous chemotherapy: cisplatin + Zephyr in our department.
    On March 7, 2010, the patient’s chest CT was reviewed and the tumor in the left lung had shrunk significantly, with only fibrosis and some non-distended lung tissue remaining, and the effect of Ar-He knife treatment was similar to surgical resection. As shown below.
 
 
    The patient was followed up with chest radiotherapy in our department. The changes of blood tumor indicators before and after the Ar-He knife surgery: CEA 3.8ug/L; NSE 36.3ug/L on November 07, 2009.
    On December 21, 2009, CEA 1.89ng/mL; NSE 18.15ng/mL.
    Feb 24, 2010 CEA 3.06ng/mL; NSE 10.06ng/mL.
     Overall comment.
    Ar-He knife treatment for lung cancer is less invasive, less painful and more effective. Postoperative combination with chemotherapy and radiotherapy can significantly reduce patients’ pain, improve their survival quality and prolong their lives. The combination of argon helium knife and radiotherapy is the best choice for lung cancer patients in the middle and late stages, the elderly and those who cannot be removed surgically.